Becton Dickinson Q4 2026 earnings
Revenue grew 5% year-over-year, but adjusted EPS declined 2% due to a 1.2 percentage-point compression in adjusted EBITDA margin.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $10.26B | +5% | +2% | Ex. 99.1, Income Statement |
| EPS (GAAP) | $1.85 | +2% | +1% | Ex. 99.1, Income Statement |
| EPS (adjusted) | $2.20 | -2% | +1% | Ex. 99.1, Income Statement |
| Net income | $1.30B | +3% | +2% | Ex. 99.1, Income Statement |
| Adj. EBITDA | $2.44B | +2% | +1% | Ex. 99.1, Income Statement |
| Adj. EBITDA margin | 23.8% | -1.2 pp | +0.3 pp | Ex. 99.1, Income Statement |
Revenue breakdown
| Segment | Actual | YoY | Share of revenue | Note |
|---|---|---|---|---|
| Medical - Surgical | $3.20B | +4% | 31% | Strong performance in U.S. and international markets |
| Interventional | $2.10B | +6% | 20% | Solid growth in catheters and guidewires |
| Diabetes Care | $2.50B | +3% | 24% | Steady demand for insulin delivery systems |
| MedTech | $2.46B | +7% | 24% | Growth in respiratory and vascular products |
Margins and costs
- Gross margin 67.6% (prior 67.8%, change -0.2 pp)
- Operating expenses $3.04B (+4% YoY)
- One-offs in the quarter Tax rate impact: 16.5% (vs 18.0% prior year); Restructuring charges: $8M
- Effective tax rate 16.5% (prior-year 18.0%, year-to-date 17.2%)
- Non-GAAP bridge Adds back stock-based compensation ($312M), amortization of intangibles ($115M), and acquisition-related costs ($45M).
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Free cash flow | $1.85B | $1.70B | $1.80B | +9% |
| Revenue backlog | $12.5B | $12.0B | $11.8B | +4% |
Guidance
| Metric | Guide | Prior guide | Change |
|---|---|---|---|
| Revenue | $10.5B - $10.7B | $10.4B - $10.6B | +0.1 pp |
| Adjusted EPS | $2.15 - $2.25 | $2.20 - $2.30 | -0.05 pp |
What drove it
- Revenue story Revenue increased 5% year-over-year, driven by strength in MedTech (+7%) and Interventional (+6%), partially offset by a 3% decline in Diabetes Care.
- EPS story Adjusted EPS declined 2% year-over-year, primarily due to a 1.2 percentage-point compression in adjusted EBITDA margin and higher operating expenses (+4%).
- One-off check Restructuring charges of $8M and a lower tax rate of 16.5% (vs 18.0% prior year) impacted the quarter.
The good
- Revenue backlog grew 4% to $12.5B
- Free cash flow increased 9% to $1.85B
The bad
- Adjusted EPS declined 2% year-over-year
- Adjusted EBITDA margin compressed 1.2 pp
The ugly
- none
Open questions
- The release does not quantify the specific impact of the lower tax rate on net income.
- The release does not disclose the specific drivers of the 3% decline in Diabetes Care revenue.
Full release
Becton Dickinson (BDX) earnings release, November 5, 2026
Attachments
Seq Document Description
───────────────────────────────────────────────────────────────────────────────
2 ex9919302026.htm Additional exhibits